June 4, 2026 June 4, 2026Categories News StoriesA new exploratory analysis from STAMP (EA6174) on aggressive Merkel cell cancer draws attention at ASCO 2026
November 3, 2025 November 3, 2025Categories News StoriesSTAMP (EA6174), the largest trial of adjuvant pembrolizumab in Merkel cell carcinoma, reports key benefit
October 30, 2025 October 30, 2025Categories News StoriesWATCH: Dr. Janice Mehnert discusses STAMP (EA6174) trial results; adjuvant pembrolizumab in resected Merkel cell carcinoma shows improved distant metastasis-free survival
October 4, 2022 October 4, 2022Categories News StoriesDREAMseq trial clarifies immunotherapy, targeted treatment order for patients with BRAF-mutant metastatic melanoma
September 30, 2022 September 30, 2022Categories News StoriesAdvanced melanoma survival improves significantly when immunotherapy is given before targeted therapy
September 28, 2022 September 28, 2022Categories News StoriesImmunotherapy before targeted therapy improves survival in advanced melanoma, according to the DREAMseq trial
September 27, 2022 September 27, 2022Categories Press ReleasesMedia Advisory: Journal of Clinical Oncology publishes outcomes from the practice-changing DREAMseq trial in patients with advanced melanoma
